Recruiting

TGFBR-2 KO CD70 CAR NK Cells for Advanced Clear Cell Renal Cell Carcinoma

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Lymphodepleting chemotherapy

+ Dexamethasone

+ Fludarabine

Drug
Who is being recruted

Adenocarcinoma+3

+ Carcinoma

+ Neoplasms

Over 18 Years
+25 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 1
Interventional
Study Start: September 2025
See protocol details

Summary

Principal SponsorM.D. Anderson Cancer Center
Study ContactAndrew C Johns, MD
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: September 25, 2025

Actual date on which the first participant was enrolled.

This study focuses on a new treatment for advanced clear cell renal cell carcinoma, a type of kidney cancer that has not responded well to other treatments. The research is investigating the use of genetically modified immune cells, known as TGFBR-2 KO CD70 CAR NK cells, to determine their safety and effectiveness. These modified cells are designed to target and attack cancer cells that have been difficult to treat with existing therapies. The goal is to understand how safe this treatment is, how well it is tolerated by patients, and to find the best dose that provides the most benefit. Participants in the study will receive this treatment through an infusion of these modified immune cells. Researchers will closely monitor participants to observe any changes in their cancer, looking for signs that the treatment may be shrinking tumors or alleviating symptoms. The study will also record any side effects or adverse reactions to ensure the safety of the treatment. The ultimate aim is to gather data that could lead to new, more effective treatment options for people with this challenging form of kidney cancer.

Official TitlePhase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma
NCT07072234
Principal SponsorM.D. Anderson Cancer Center
Study ContactAndrew C Johns, MD
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

30 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

AdenocarcinomaCarcinomaNeoplasmsNeoplasms by Histologic TypeNeoplasms, Glandular and EpithelialAdenocarcinoma, Clear Cell

Criteria

25 exclusion criteria prevent from participating
Presence of clinically significant ongoing Grade ≥ 2 toxicity unequivocally associated withthe previous anticancer treatment, as determined by the PI. Toxicities related to priorsurgery, radiation, prior systemic immune checkpoint inhibitors and chemotherapy should be resolved to Grade 1 or below prior to lymphodepletion.
Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management or not responding to appropriate therapy. Note: Participants with simple urinary tract infection and uncomplicated bacterial pharyngitis are permitted if responding to active treatment.
Known active hepatitis B or C.
Known human immunodeficiency virus (HIV).
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental

Group II

Experimental

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

MD Anderson Cancer Center

Houston, United StatesOpen MD Anderson Cancer Center in Google Maps
Recruiting
One Study Center